2017 Investment Summit on Healthcare Industry Held, Paving the Way for a New Development Paradigm

On June 22, the “2017 VCBeat Greater Health Investment Summit,” co-hosted by Zero2IPO Group, VCBeat, and the China Healthcare Industry Investment 50-Person Forum, was successfully held in Shanghai. With a focus on leveraging equity investment to promote the development of the healthcare industry, the summit attracted nearly 1,000 industry representatives and featured insights from over 100 business leaders, partners from leading investment firms, and renowned experts in the greater health sector.

As a sector vital to public well-being, the big health industry has spawned vast market potential and investment opportunities. Against this backdrop, the summit has drawn widespread attention from the industry and received strong support from numerous institutions, including Shengshijing Asset Management Group, GTJA Investment Group, IDG Capital, Lenovo Ventures, CDH Investments, Northern Light Venture Capital, Cowin Capital, Huagai Capital, Hualing Group, and Vertex Venture Capital.

The summit focuses on the frontiers and current hotspots of the broader healthcare industry. Keeping pace with the times, the organizers have curated multiple topics, including pharmaceuticals, mergers and acquisitions, smart health, health services and management, and tiered diagnosis and treatment. Through diverse formats such as keynote speeches, in-depth sharing sessions, and roundtable discussions, the event showcases multidimensional intellectual exchanges and insights for attendees.

First, Zhang Zhenzhong, Vice President and Secretary-General of the Chinese Society for Health Economics, officially opened the summit with his address titled “Healthy China 2030 and the Development of the Health Industry.”

Xu Xiaolin, Chairman of Huagai Capital, Executive Chairman of Liang·China, and the inaugural Chairman of the China Healthcare Industry Investment 50 Forum (H50), pointed out on the topic of “The 2.0 Era of Investment in China’s Healthcare Industry” that the golden age has passed. Recently, many have noted that trends in China’s capital markets are similarly reflected in healthcare investment, indicating that the era of liquidity dividends is over.

In recent years, the healthcare industry has ushered in an era of turbulent transformation, with marketization trends gradually spreading. However, how to seize the initiative amidst this tidal wave of change has remained a hotly debated topic within the private equity investment sector. During the session titled “Investment Circle Talks: The Capital Sniper Battle in the Era of Big Health,” Jin Jiong, Managing Partner at Vertex Venture Capital, served as the moderator and engaged in a lively discussion with Hu Xubo, Managing Partner at Qiming Venture Partners; Wang Yang, Managing Director at Cowin Capital; Yang Yunxia, Managing Director at Sequoia Capital China; Zhao Gang, Founding Partner at HighLight Capital; Zhang Haifeng, Partner at CDH Investments’ Innovation and Growth Fund; and Zhou Quan, Partner and Executive Director at Legend Capital.

Currently, pharmaceutical innovation has become a focal point in the healthcare sector. Following the Two Sessions, the pharmaceutical industry, as a key area of reform, has once again sparked widespread discussion. At this summit, Yuan Quanhong, President and Partner of CCB Capital and Director of the China Healthcare Industry Investment 50 Forum (H50), stated during the keynote interview session titled “Reshaping the Pharmaceutical Market Landscape—Major Opportunities Amidst Significant Changes” that the lengthy cycle of new drug development necessitates a slightly longer fund term, thereby ensuring alignment between capital and investee companies.

In the afternoon session of the summit, Wu Minwen, Chairman of Shengshijing Group, shared his insights on full-industry-chain layout in the broad health sector. He argued that, from the perspective of investment and capital in China, spanning from financial full-industry-chain services to corporate life cycles offers two advantages: mitigating financial cycle risks and creating more investment opportunities.

The summit also conducted an in-depth discussion on the hot topic of mergers and acquisitions (M&A) in recent years. Regarding the M&A boom and integration in healthcare, Huang Qing, Executive Deputy General Manager and Managing Partner at GTJA Investment Group, noted that the characteristics of the medical device industry necessitate continuous platform expansion through acquisitions. Meanwhile, the summit invited major healthcare groups such as CITIC Private Equity Funds Management, Medbo Tech Group, Capital Medical Industry Group, Peking University Healthcare Industry Group, and Yide Medical Investment Management Group to provide insightful interpretations of their respective strategic directions and layouts concerning industrial trends in the broader health sector. These discussions covered multiple aspects, including investment and M&A in healthcare services, cross-border M&A, and M&A under new business models.